- Home
- RNG vs CELC Comparison
RNG vs CELC Comparison
Compare RNG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | CELC |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RNG | CELC |
|---|---|---|
| Price | $47.19 | $144.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 9 |
| Target Price | $33.58 | ★ $112.56 |
| AVG Volume (30 Days) | ★ 1.4M | 722.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 176.19 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $2,515,142,000.00 | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.56 | $720.19 |
| P/E Ratio | $94.34 | ★ N/A |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $23.59 | $9.64 |
| 52 Week High | $46.11 | $129.09 |
Technical Indicators
Market Signals| Indicator | RNG | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 70.98 | 68.83 |
| Support Level | $25.56 | $100.58 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.19 | 8.08 |
| MACD | 0.57 | 1.26 |
| Stochastic Oscillator | 91.42 | 85.58 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.